Journal Club: Gene-Agnostic Gene Therapy to Preserve Vision
Striatech is pleased to announce its next Journal Club: Gene-Agnostic Gene Therapy to Preserve Vision, which will be held on
Read moreStriatech is pleased to announce its next Journal Club: Gene-Agnostic Gene Therapy to Preserve Vision, which will be held on
Read moreBoosting RPE Metabolic Support Offers a Promising Gene-Independent Strategy for RP Treatment A Striatech .pdf Case Study Retinitis Pigmentosa (RP)
Read moreA recent study from Constance Cepko’s group at Harvard Medical School offers an encouraging advance toward therapeutic strategies for Retinitis
Read moreAerska, a newly formed biotechnology company focused on transforming the treatment of neurological diseases, has officially launched with $21 million
Read moreA recent study by Janos Groh and colleagues in Mikael Simons’ group at the Institute of Neuronal Cell Biology, Technical
Read moreStressMarq Biosciences, a market leader and pioneer in the field of fibrilized and oligomeric protein preparations for neurodegenerative disease research,
Read moreRetinal degeneration represents a primary cause of irreversible blindness, with both its onset and severity differing significantly among various conditions.
Read moreSeNostic is Revolutionising Neurodegenerative Disease Detection and Drug Discovery with Cutting-Edge Technology A SeNostic Company Presentation SeNostic aims to enhance
Read moreStriatech, a leader in preclinical vision research devices and tools, has unveiled its New Non-Aversive Animal Platform for the OptoDrum
Read moreSanofi has announced a definitive agreement to acquire clinical-stage biotech firm Vigil Neuroscience, Inc., in a move to expand its
Read more